DE19721700C1 - Mutierter OKT3-Antikörper - Google Patents

Mutierter OKT3-Antikörper

Info

Publication number
DE19721700C1
DE19721700C1 DE19721700A DE19721700A DE19721700C1 DE 19721700 C1 DE19721700 C1 DE 19721700C1 DE 19721700 A DE19721700 A DE 19721700A DE 19721700 A DE19721700 A DE 19721700A DE 19721700 C1 DE19721700 C1 DE 19721700C1
Authority
DE
Germany
Prior art keywords
monoclonal antibody
okt3
expression
vector
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE19721700A
Other languages
German (de)
English (en)
Inventor
Sergey Dr Kipriyanov
Melvyn Prof Dr Little
Gerhard Dr Moldenhauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Priority to DE19721700A priority Critical patent/DE19721700C1/de
Priority to EP98934774A priority patent/EP0983302B1/de
Priority to DE59813519T priority patent/DE59813519D1/de
Priority to AT98934774T priority patent/ATE324381T1/de
Priority to ES98934774T priority patent/ES2263212T3/es
Priority to PCT/DE1998/001409 priority patent/WO1998052975A1/de
Priority to JP54981698A priority patent/JP4276302B2/ja
Application granted granted Critical
Publication of DE19721700C1 publication Critical patent/DE19721700C1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE19721700A 1997-05-23 1997-05-23 Mutierter OKT3-Antikörper Expired - Fee Related DE19721700C1 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE19721700A DE19721700C1 (de) 1997-05-23 1997-05-23 Mutierter OKT3-Antikörper
EP98934774A EP0983302B1 (de) 1997-05-23 1998-05-22 Mutiertes ScFv-Fragment des OKT-3 Antikörpers
DE59813519T DE59813519D1 (de) 1997-05-23 1998-05-22 Mutiertes ScFv-Fragment des OKT-3 Antikörpers
AT98934774T ATE324381T1 (de) 1997-05-23 1998-05-22 Mutiertes scfv-fragment des okt-3 antikörpers
ES98934774T ES2263212T3 (es) 1997-05-23 1998-05-22 Anticuerpo okt3 mutado.
PCT/DE1998/001409 WO1998052975A1 (de) 1997-05-23 1998-05-22 Mutierter okt3-antikörper
JP54981698A JP4276302B2 (ja) 1997-05-23 1998-05-22 突然変異させたｏｋｔ３抗体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19721700A DE19721700C1 (de) 1997-05-23 1997-05-23 Mutierter OKT3-Antikörper

Publications (1)

Publication Number Publication Date
DE19721700C1 true DE19721700C1 (de) 1998-11-19

Family

ID=7830336

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19721700A Expired - Fee Related DE19721700C1 (de) 1997-05-23 1997-05-23 Mutierter OKT3-Antikörper
DE59813519T Expired - Lifetime DE59813519D1 (de) 1997-05-23 1998-05-22 Mutiertes ScFv-Fragment des OKT-3 Antikörpers

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE59813519T Expired - Lifetime DE59813519D1 (de) 1997-05-23 1998-05-22 Mutiertes ScFv-Fragment des OKT-3 Antikörpers

Country Status (6)

Country Link
EP (1) EP0983302B1 (https=)
JP (1) JP4276302B2 (https=)
AT (1) ATE324381T1 (https=)
DE (2) DE19721700C1 (https=)
ES (1) ES2263212T3 (https=)
WO (1) WO1998052975A1 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2003531149A (ja) 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2971647T3 (es) 2005-04-15 2024-06-06 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
PL2573114T3 (pl) 2005-08-10 2016-10-31 Identyfikacja i inżynieria przeciwciał z wariantami regionów FC oraz sposoby ich stosowania
WO2008105886A2 (en) 2006-05-26 2008-09-04 Macrogenics, Inc. HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
ES2599319T3 (es) 2006-06-26 2017-02-01 Macrogenics, Inc. Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
US8795667B2 (en) 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
ES2589912T3 (es) 2008-04-02 2016-11-17 Macrogenics, Inc. Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
WO2009123894A2 (en) 2008-04-02 2009-10-08 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
JP5898082B2 (ja) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
AU2011286024B2 (en) 2010-08-02 2014-08-07 Macrogenics, Inc. Covalent diabodies and uses thereof
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
BR112013029892A2 (pt) 2011-05-21 2016-12-20 Macrogenics Inc polipeptídeo, molécula de ligação a antígeno, diacorpo e uso de uma porção polipeptídica de uma proteína de ligação a soro desimunizada
WO2013188693A1 (en) * 2012-06-15 2013-12-19 Imaginab, Inc. Antigen binding constructs to cd3
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd８에의 항원 결합 구조체들
SMT202100464T1 (it) 2013-03-14 2021-11-12 Macrogenics Inc Molecole bispecifiche che sono immunoreattive con cellule effettrici immunitarie che esprimono un recettore di attivazione
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
MX386297B (es) 2014-09-29 2025-03-18 Univ Duke Moleculas biespecificas que comprenden un brazo orientado a la envoltura vih-1.
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
EP3091032A1 (en) 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
GEP20227398B (en) 2016-04-15 2022-07-25 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hum. Antibod. Hybridomas, 1994, Vol. 5, 1 und 2, S. 41-47 *

Also Published As

Publication number Publication date
ES2263212T3 (es) 2006-12-01
JP2001527414A (ja) 2001-12-25
WO1998052975A1 (de) 1998-11-26
EP0983302A1 (de) 2000-03-08
DE59813519D1 (de) 2006-06-01
JP4276302B2 (ja) 2009-06-10
EP0983302B1 (de) 2006-04-26
ATE324381T1 (de) 2006-05-15

Similar Documents

Publication Publication Date Title
DE19721700C1 (de) Mutierter OKT3-Antikörper
DE60127143T2 (de) Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung
EP1078004B1 (de) Tetravalente Antikörperkonstrukte
DE69434578T2 (de) Expressionsvektoren die für bispezifische Proteine kodieren, und Verfahren zur Herstellung von biologisch-aktiven bispezifischen Fusionsproteinen in Zellen von Säugetieren
DE69133179T2 (de) Katalytische antikörperkomponente
US5939531A (en) Recombinant antibodies specific for a growth factor receptor
EP1566442B1 (de) Herstellung und Verwendung von Genbanken menschlicher Antikörper("Human-Antikörper-Bibliotheken")
DE60124912T2 (de) Multimerische, einzelkettige, Tandem-Fv-Antikörper
DE60133479T2 (de) Modifizierter tpo-agonisten antikörper
DE102010039018B4 (de) Anti-La Antikörper und ihre Anwendung zum Immunotargeting
WO2004024771A1 (en) Human cd3-specific antibody with immunosuppressive properties
HU229039B1 (en) Cd19xcd3 specific polypeptides and uses thereof
DE102011118022A1 (de) Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
DE60118370T2 (de) Leader-anteile zur erhöhung der sekretion von rekombinanten proteinen aus einer wirtzelle
DE60214127T2 (de) Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper
EP0720623B1 (de) Monoklonale antikörper gegen leukozyten-spezifische g-protein-gekoppelte rezeptoren
DE3853481T2 (de) Fv Antikörperfragment-Herstellung.
DE69020112T2 (de) Spezifische bindende Wirkstoffe.
DE69216600T2 (de) Synthetisches CDw52(CAMPATH-1) Peptidantigen
EP1141271A1 (de) Selektion von monoklonalen antikörpern
DE69230659T2 (de) Polypeptide, die an die schweren Ketten von IL-2-Rezeptoren binden können
WO2001027159A2 (de) Polypeptide zur detektion und elimination ca19-9 antigen positiver zellen
EP1015583B1 (de) Srcr domäne-enthaltendes protein
EP1092769B1 (de) Polypeptid-Tag's für den Nachweis und die Aufreinigung von Polypeptiden
DE10013286A1 (de) Humane FAP-alpha-spezifische Antikörper

Legal Events

Date Code Title Description
8100 Publication of patent without earlier publication of application
D1 Grant (no unexamined application published) patent law 81
8364 No opposition during term of opposition
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20111201